IDH2 and glioma: In this study, we examined the use of whole-genome DNA methylation array (WGMA) testing to identify IDH1/IDH2 pathway disruption, through the detection of CIMP, in addition to the characterization of additional molecular alterations that may assist in the classification of glioma tumors.